References
- Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495 - 497
- Das RC, Morrow KJ. Antibody technologies rise to new challenges. Am Biotechnol Lab 2007; 25:9 - 11
- Butler M. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol 2005; 68:283 - 291
- 5th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2008; Bioplan Associates, Inc
- Source: US Federal Reserve Statistical Release, Industrial Production Capacity and Utilization 2008;
- Source: US Federal Reserve Statistical Release, Industrial Production Capacity and Utilization 2008; November 17 2008 http://www.federalreserve.gov/releases/G17/Current/
- Ranshoff T. According to industry data, by 2005, the biopharmaceutical contract manufacturing industry had grown to an estimated $1.5 billion. CMOs now hold between 15–29% of the industry-wide capacity for both mammalian cell culture and microbial fermentation. BioPharm International 2007;
- Morin N, Stevens J. Diverging Measures of Capacity Utilization: An Explanation, Divisions of Research & Statistics and Monetary Affairs, Federal Reserve Board 2004; 2009 Washington DC http://www.federalreserve.gov/pubs/feds/2004/200458/200458pap.pdf